| SEC Form 4 | |
|------------|--|
|------------|--|

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

| OMB Number: | 3235-0287 | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Steinhart Richard I</u> | | | 2. Issuer Name and Ticker or Trading Symbol BioXcel Therapeutics, Inc. [BTAI] | 5. Rela (Check | son(s) to Issuer 10% Owner | | | | | |
|--|--|-------|---|-------------------|--|-----------------------|--|--|--|--|
| | (First) (Middle) EL THERAPEUTICS, INC., | | 3. Date of Earliest Transaction (Month/Day/Year) 02/01/2021 | X | Director Officer (give title below) Chief Financial | Other (specify below) | | | | |
| 555 LONG WHARF DRIVE | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check | | | | | | | |
| (Street) NEW HAVEN | СТ | 06840 | | Line) | Form filed by One Repo Form filed by More thar Person | 0 | | | | |
| (City) | (State) | (Zip) | | | reisui | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | |

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | Transaction Code (Instr. | | 4. Securities Disposed Of | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership |
|---------------------------------|--|-----------------------------|---|------------------------------|---------------|------------|---|---|---|
| | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (Instr. 4) |
| Common Stock | 02/01/2021 | М | | 3,750 | A | \$5.55 | 5,250 | D | |
| Common Stock | 02/01/2021 | S ⁽¹⁾ | | 3,750 | D | \$48.15(2) | 1,500 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| (| | | | | | | | | | | | | | | |
|---|---|--|---|------------------------------|---|--|------------------------|-------------------------------------|--------------------|-----------------|--|---|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of Deri Sec Acq (A) (Disp of (I | osed)) tr. 3, 4 | Expiration Date (Month/Day/Year) | | te Amount of | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Option | \$5.55 | 02/01/2021 | | м | | | 3,750 | (3) | 10/02/2027 | Common Stock | 3,750 | \$0 | 80,148 | D | |

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$48.00 to \$48.73. The reporting person undertakes to provide BioXcel Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The shares underlying this stock option vested and became exercisable as to 21,093 shares on October 1, 2018, and the remaining 62,805 shares have vested or will vest monthly over 36 months from October 2, 2018 through October 1, 2021.

<u>/s/ Richard I. Steinhart</u> <u>C</u>

** Signature of Reporting Person

<u>02/03/2021</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.